on B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Secures Licensing Deal with Akribion Therapeutics
BRAIN Biotech AG, based in Zwingenberg, Germany, has entered an exclusive licensing agreement with Akribion Therapeutics GmbH. This agreement covers BRAIN's G-dase E® CRISPR-Cas genome editing technology, specifically for pharmaceutical applications. The potential financial gain for BRAIN includes up to EUR 92.3 million through milestone fees and royalties.
The deal is structured around Akribion's progress in clinical development and market performance. Outside of pharmaceuticals, BRAIN retains the rights to utilize G-dase E® technology in its core business areas. This agreement is pending customary closing conditions.
Akribion Therapeutics is independently owned and funded by venture capital. The transaction underscores the potential financial growth for BRAIN through strategic partnerships.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news